Regulus Therapeutics (RGLS) Misses Q3 EPS by 4c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Rockstar Energy founder seeks CEO role at Celsius Holdings
• Bimini Capital Management (BMNM) Tops Q2 EPS by 4c
• Citi Downgrades Legal & General Group PLC (LGEN:LN) (LGGNF) to Sell